Key Points
- CEO Roger Susi sold 5,000 shares of iRadimed on Jan. 12 at an average price of $97.45 for about $487,250, trimming his stake by 0.22% to 2,272,500 shares valued near $221.46M.
- iRadimed beat expectations last quarter with $0.47 EPS vs. $0.43 expected and $21.2M revenue vs. $20.5M, and provided Q4 2025 guidance of $0.470–0.510 EPS and FY2025 guidance of $1.840–1.880 EPS.
- Dividend, ownership and analyst backdrop: the company paid a $0.50 special dividend (DPR ~41%), has a $1.26B market cap and ~92% institutional ownership, and carries a "Moderate Buy" analyst consensus with an $87.33 average price target.
iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 5,000 shares of the company's stock in a transaction on Monday, January 12th. The shares were sold at an average price of $97.45, for a total value of $487,250.00. Following the sale, the chief executive officer directly owned 2,272,500 shares of the company's stock, valued at approximately $221,455,125. This represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
iRadimed Stock Up 1.4%
NASDAQ:IRMD opened at $99.25 on Wednesday. The stock has a fifty day simple moving average of $93.37 and a 200 day simple moving average of $77.62. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of 60.15 and a beta of 1.09. iRadimed Corporation has a 1-year low of $47.48 and a 1-year high of $100.39.
iRadimed (NASDAQ:IRMD - Get Free Report) last posted its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, beating analysts' consensus estimates of $0.43 by $0.04. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. The company had revenue of $21.20 million during the quarter, compared to analyst estimates of $20.50 million. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. Equities analysts predict that iRadimed Corporation will post 1.66 earnings per share for the current year.
iRadimed Announces Dividend
The company also recently disclosed a special dividend, which was paid on Tuesday, December 30th. Investors of record on Wednesday, December 17th were paid a $0.50 dividend. The ex-dividend date of this dividend was Wednesday, December 17th. iRadimed's dividend payout ratio (DPR) is currently 41.21%.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. Royal Bank of Canada lifted its holdings in shares of iRadimed by 14.7% during the 1st quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider's stock valued at $1,354,000 after buying an additional 3,307 shares during the last quarter. AQR Capital Management LLC raised its position in iRadimed by 7.5% during the first quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider's stock valued at $831,000 after acquiring an additional 1,108 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in iRadimed by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider's stock valued at $252,000 after acquiring an additional 234 shares during the last quarter. Jones Financial Companies Lllp lifted its stake in iRadimed by 8,568.5% in the first quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider's stock valued at $591,000 after acquiring an additional 11,139 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its position in iRadimed by 1.1% in the first quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider's stock worth $8,889,000 after acquiring an additional 1,821 shares in the last quarter. 92.34% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on the company. Zacks Research upgraded iRadimed to a "hold" rating in a report on Tuesday, November 4th. Roth Capital set a $90.00 price objective on iRadimed in a research note on Friday, October 31st. Weiss Ratings restated a "buy (b-)" rating on shares of iRadimed in a research report on Monday, December 29th. Wall Street Zen cut iRadimed from a "strong-buy" rating to a "buy" rating in a research note on Sunday, October 26th. Finally, Lake Street Capital reissued a "buy" rating and issued a $100.00 price target on shares of iRadimed in a research report on Monday, November 3rd. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $87.33.
Get Our Latest Report on iRadimed
About iRadimed
(
Get Free Report)
iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.
In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
